Abstract
Thorotrast (a colloidal suspension of thorium dioxide) was introduced to the radiological armamentarium in 19281and rapidly achieved widespread popularity as a contrast medium for cerebral angiography, hepatolienography, myelography, and salpingography. Since that time the accumulation of cases of malignant disease, fibroses of vital structures, and anemias which might be attributed to thorium dioxide has virtually prohibited its use, although doubts have been raised concerning the mechanism of their causation. This literature has been recently reviewed by Looney.2 Although the majority of carcinomas that occur after administration of thorium dioxide suspension are found in the liver,2local tumor induction has also been reported in man3and animals.4This induction is well illustrated by the following case. A 48-year-old Portuguese woman underwent salpingography as part of a sterility investigation in 1938. Presumably a colloidal suspension of thorium dioxide was the radiopaque agent employed. Apparently at least
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.